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STATEMENT OF TRANSLATIONAL RELEVANCE
The cMET oncogene is implicated in tumorigenesis and chemoresistance and it is also implicated in the pathogenesis and progression of multiple myeloma (MM). Here we studied sensitive and drugresistant MM cell lines and patients, and show that cMET pathway is involved in MM relapse and resistance to therapy and that p-cMET is a marker of major response to the cMET inhibition. A novel selective c-MET inhibitor SU11274 was able to exert significant therapeutic activity in a MM xenograft model. Our results offer preclinical rationale for targeting this pathway in relapsed and refractory MM. 
INTRODUCTION
The hepatocyte growth factor (HGF) receptor cMET is an oncogene that mediates growth, invasion, and metastasis of several tumors, including breast (1), colorectal (2) , and lung carcinoma (3) , and promotes angiogenesis (4) . The cMET is also implicated in resistance to both chemotherapeutics (5) and inhibitors of receptors of vascular endothelial growth factor (6) and epidermal growth factor (7) . The cMET and its phosphorylated content as phospho-cMET (p-cMET) are associated with poor survival in colorectal (8) and lung cancer (9) , as well as with disease progression in breast cancer (10) and melanoma (11) .
Børset et al. first described the significance of the cMET in the pathogenesis and progression of multiple myeloma (MM) (12) , then observations have been extended to other hematological tumors (13). MM plasma cells (PCs) express cMET and often simultaneously HGF (14) as an autocrine loop, while a paracrine loop between cMET-expressing PCs and HGF-secreting microenvironment cells has been found (15) . HGF also enhances IL-6, a PCs growth factor (16) . HGF and cMET are listed in MM-related genes (17) .
HGF and the induced p-cMET are crucial in the MM progression: HGF levels in blood and bone marrow plasma are substantially increased in newly diagnosed patients compared to healthy controls (18) ; its serum levels correlate with the Durie & Salmon stage (19) , and high levels imply poor prognosis (20) ; its bone marrow plasma levels decrease with successful treatment response, while high pre-treatment serum levels mark resistance to high-dose chemotherapy (21) and bortezomib (22) .
To date the role of cMET/p-cMET as a possible pathway mediating MM drug resistance remains still unexplored. Also, inhibition of the pathway as a therapeutic approach to several tumors is being developed (23) , while information on MM remains circumstantial (14) . Among novel cMET inhibitors, SU11274 is a tyrosine kinase inhibitor (TKI) highly specific for cMET that inhibits HGF-induced p-cMET and its downstream signaling (3).
Research. Here we studied sensitive and drug resistant MM cell lines and patients' PCs, and show that cMET/p-cMET are involved in MM relapse and resistance to therapy, and that SU11274 offers in both in vitro and in vivo assays a preclinical rationale for targeting this pathway in relapsed and resistant MM patients.
Materials and methods

Patients and cell isolation
Patients fulfilling the International Myeloma Working Group diagnostic criteria (24) for MM (n = 46) and MGUS (n = 18) were studied. Newly diagnosed MM patients (n = 14), patients at relapse after one to three therapy lines based on bortezomib and/or thalidomide or lenalidomide in conjunction with melphalan or doxorubicin plus prednisone or dexamethasone, or on resistant phase to these drugs (n = 18), or on complete/partial remission (n = 14) were studied. They were 27 men and 19 women, ages 47 to 86 years (median 63.5). The MGUS patients were 11 men and 7 women, ages 41 to 80 years (median 61.5). Eleven patients with anemia due to iron or vitamin B 12 deficiency were studied as controls (25) . The study was approved by the Ethics Committee of the University of Bari Medical School, and patients gave their informed consent in accordance with the declaration of Helsinki.
Bone marrow mononuclear cells (BMMCs) were isolated from heparinized aspirates by the Ficoll gradient: plasma cells (PCs) were obtained with magnetic anti-CD138 beads (Immunotech, Marseille, France) while adherent CD138-cells were cultured separately as bone marrow stromal cells (BMSCs). Fibroblasts were purified from BMSCs of five newly diagnosed MM patients through D7-FIB-conjugated (anti-fibroblasts) microbeads (Miltenyi) (26) , and cultured in DMEM medium with 20% fetal bovine serum (FBS, Sigma, St. Louis, MO, USA). Cells were grown to 80% confluence and incubated in serum-free DMEM medium for 48 h. Culture supernatants were centrifuged (200×g for 10 min), and stored at -80°C as conditioned media (CM).
Research. (28) . The cell lines were cultured in RPMI-1640 medium supplemented with 10% FCS (both from Euroclone, Milan, Italy). The selective phospho(p)-cMET inhibitor SU11274 (Selleck Chemicals, Huston, TX, USA) was dissolved in DMSO at 0.1÷1 μM for in vitro studies (29) while it was dissolved in 1% Tween 80 (Sigma-Aldrich Co., St. Louis, MO, USA) and administered at 100 mg/kg/day for in vivo mouse studies (30) . In other in vivo experiments bortezomib (Selleck Chemicals) was dissolved in PBS and injected intraperitoneally once a week at the dose of 1 mg/Kg. A monoclonal antibody to human HGF (R&D Systems, Inc., Minneapolis, MN, USA) was used at 0.1÷0.3 μg/mL for the HGF blockade; an anti-human cMET antibody (R&D Systems) was used at 0.5÷2 μg/mL for the cMET blockade in vitro.
Real-Time RT-PCR, immunoprecipitation and Western blot
These were performed as described (31) , and are detailed in supporting information to this manuscript (Supplementary Materials and Methods).
Preparation of conditioned media (CM) and enzyme-linked immunosorbent assay (ELISA)
MM cell lines (1.5×10 6 cells/mL) were cultured for 24 h in serum-free medium (SFM) 1% glutamine, then supernatants centrifuged, concentrated, and stored at -80°C as CM (31) . HGF was quantified in CM by an ELISA (R&D Systems, Inc.).
Fluorescence-activated cell sorting (FACS)
This was performed on BMMCs and MM cell lines as detailed in supporting information to this
manuscript (Supplementary Materials and Methods).
Research. 
Functional studies
Viability, chemotaxis, adhesion, proliferation, and apoptosis assays were performed on both primary PCs and MM cell lines as described (25) 
Results
Multidrug resistant MM cells present with a constitutive activation of cMET pathway
Research. Expression of cMET and HGF was evaluated in MM cell lines either sensitive (RPMI8226) or multiresistant (R5) to anti-MM drugs. R5 cells presented with lower levels of HGF ( Figure 1A ) and higher levels of cMET mRNA ( Figure 1B) ; accordingly, cells showed lower HGF secretion ( Figure   1C ) and higher total cMET and phospho(p)-cMET protein expression ( Figure 1D ). Expression of cMET and p-cMET was also analyzed by flow cytometry on the cells cultured in serum-free medium (SFM): 90 + 8% of R5 cells co-expressed cMET and p-cMET, whereas RPMI8226 cells showed co-expression in only 52 + 5% of cells, while 28 + 6% expressed cMET alone ( Figure 1E ).
Furthermore in SFM a HGF neutralizing antibody was able to reduce markedly p-cMET expression in RPMI8226 but not in R5 cells ( Figure 1F ). Overall findings indicate that R5 cells present with a high HGF-independent p-cMET content, i.e., with a constitutive activation of the cMET receptor.
The increase of p-cMET levels on drug-resistant MM cells was confirmed in the other pair of isogenic MM cell lines: specifically, higher p-cMET expression was found on the dexamethasone- Figure   S1A ).
resistant (MM.1R) than on the dexamethasone-sensitive (MM.1S) cells (Supplementary
SU11274 exerts major anti-tumor activity in multidrug resistant MM cells
The cMET pathway supports viability of MM plasma cells (PCs) (32) as well as their chemotaxis and adhesion by enhancing respectively metalloproteinase 9 (33) and VLA-4 expression (34). average at 1 μM; P < 0.001; Wilcoxon signed-rank test; Supplementary Figure S1B) . In R5 cells, SU11274 inhibited more potently: i) chemotaxis toward both HGF ( Figure 2B ) and conditioned media of BM fibroblasts derived from newly diagnosed MM patients (Supplementary Figure S3B) ;
ii) adhesion to fibronectin ( Figure 2C ) and to relapsed/resistant MM patients' bone marrow stromal cells (BMSCs) ( Figure 2D ). All inhibitory effects were dose-dependent.
The p-cMET inhibition produces apoptosis and prolonged anti-proliferative effects in R5 cells, and reverts their bortezomib, melphalan and doxorubicin resistance
Next we evaluated the effects of SU11274 on cell apoptosis and proliferation by using PI-and CFSE-staining, respectively. R5 and RPMI8226 cells were cultured in SFM with SU11274 (range:
0÷1 µM) for 6, 12, and 24 h. Multidrug resistant R5 cells gave irrelevant percentages of spontaneous apoptosis at each time point (9%, 7% and 8%, respectively, Figure 3A , panels X, XIII and XVI) compared to RPMI8266 cells (19%, 30% and 41%, Figure 3A , panels I, IV and VII) that may be related to the higher p-cMET expression ( Figure 1D,E) . The SU11274 treatment induced potent apoptosis only in R5 cells: ∼7 folds higher apoptosis levels with 1 μM respect to 0 μM at 24 h vs. only ∼2 folds higher in RPMI8226 cells ( Figure 3A , panels XVIII and XVI vs. IX and VII).
Worth of note is that the 6-h SU11274 treatment did not induce apoptosis in both R5 and RPMI8226 cells ( Figure 3A , panels I-III and X-XII), implying that the inhibition of p-cMET expression ( Figure 2A ) and activities of R5 cells ( Figure 2B-D) that were studied within 6 h were independent of the drug's apoptogenic effect. SU11247 inhibited cell proliferation at each time point more strongly in R5 cells ( Figure 3B , green squares). As an example, at 24 h proliferating R5 cells (blue peaks) were 26% and 17% at 0.5 and 1 µM while 100% at 0 μM ( Figure 3B , panels XVI-XVIII) vs. 98%, 96% and 99% of RPMI8266 cells (panels VII-IX). These findings suggest that p-cMET inhibition is able to exert a potent apoptogenic and anti-proliferative effect only on the highly expressing p-cMET R5 cells.
It has been previously shown that cMET knockdown by siRNA in U266 MM cells increases sensitivity to both bortezomib and doxorubicin (35) (36) . We thus wondered whether p-cMET inhibition by SU11274 might revert the resistance to bortezomib, melphalan, and doxorubicin in R5 cells: SU11274 in combination with both bortezomib and doxorubicin successfully targeted these cells in a synergistic way (combination index [CI] <1; isobologram analysis; Figure 3C) ; and with melphalan gave additive effect (CI=1, Figure 3C ). SU11274 thus rendered R5 cells as sensitive to the anti-MM drugs as RPMI8226 cells, suggesting that it may overcome drug resistance.
The cMET inhibition leads to a differential modulation of genes and phospho-proteins in sensitive and multidrug resistant MM cells
Previous studies have analyzed R5 and RPMI8226 cells at gene level, and demonstrated differentially expressed genes involved in the regulation of cell survival, growth, cytostructure, cellmicroenvironment contacts, cholesterol biosynthesis, and protein degradation (27) . Here we wondered whether p-cMET inhibition could lead to a differential modulation of genes in R5 cells isoforms, and of Pyk2, Creb and eNOS, and enhancement of Lyn, Src and mTOR p-proteins ( Figure   4B ). Similar results were obtained using an anti-cMET neutralizing antibody (Supplementary Figure S4) . Overall data suggest that multidrug resistant, highly expressing p-cMET R5 cells are dependent on the cMET receptor phosphorylation especially for the downstream modulation of the MAPK pathways that are primarily involved in MM cell growth and survival (38) .
cMET and p-cMET expressions reflect the MM disease status
We investigated whether cMET and p-cMET levels could change in MM patients with newly relapsed/resistant disease reduced more strongly the p-cMET expression than PCs from newly diagnosed patients (-66% vs. -21% as average at 1 μM, P < 0.001; Wilcoxon signed-rank test; Figure 5B ; and Supporting Information, Supplementary Figure S2B) , overlapping what was found in R5 vs. RPMI8226 cells (Figure 2A) . Also, inhibition by SU11274 of HGF-driven chemotaxis, and cell adhesion to both fibronectin and paired BMSCs was more evident in PCs from relapsed/resistant patients ( Figure 5C -E) than in those from newly diagnosed patients (Supporting Information, Supplementary Figure S5A-C) . All effects were, again, dose-dependent. Finally, the 24-h drug treatment induced, dose-dependently, cytotoxicity on PCs from relapsed/resistant patients ( Figure 5F ), but not on BMMCs from control patients ( Figure 5G) , and reverted the bortezomib resistance of these PCs through a synergistic interaction ( Figure 5H ). In contrast, minimal cytotoxic effects were observed at higher doses in PCs from newly diagnosed patients (Supporting Information, Supplementary Figure S5D ) together with little additive cytotoxicity with bortezomib ( Supporting Information, Supplementary Figure S5E) . Overall results confirm that highlyexpressing p-cMET PCs from relapsed/resistant patients are more prone to be inhibited by SU11274 much in the same way as R5 cells.
SU11274 targets MM cells in vivo
The in vitro findings were validated using NOD-scid mice, which were xenotransplanted with R5 or RPMI8226 cells, and treated with SU11274 (100 mg/kg/day; per os (30)) or vehicle. SU11274 was able to delay the growth of R5 ( Figure 6A ) more strongly than that of RPMI8226 plasmocytomas (Supplementary Figure S6A) , indicating significant anti-tumor activity in multidrug resistant MM cells (P < 0.05 or better; two-way ANOVA and Bonferroni post-test). Furthermore, SU11274 overcame bortezomib resistance: when R5 plasmocytomas were treated with SU11274 and bortezomib the tumor growth was significantly slowed down compared with bortezomib alone (Supplementary Figure S6B ; P < 0.001; log-rank test and Bonferroni test).
Research. Moreover, SU11274-treated mice presented with a longer survival, as compared to vehicle-treated mice ( Figure 6B ; P < 0.01; log-rank test and Bonferroni test). Importantly, in the treatment period no signs of toxicity were observed, as assessed by closely monitoring mice for clinical condition and body weight (data not shown). These findings were further corroborated by evaluating necrosis and apoptosis in harvested plasmocytomas: SU11274-treated mice, as compared to vehicle-treated mice, presented with a significantly higher percentage of mean necrotic area ( Figure 6C ; P < 0.01;
Wilcoxon signed-rank test), together with a significantly higher percentage of apoptotic cells ( Figure 6D ; P < 0.01; Wilcoxon signed-rank test). Finally, flow cytometry analysis on tumor cells harvested from plasmocytomas of SU11274-vs. vehicle-treated mice showed very low p-cMET expression in the former ( Figure 6E , panels I and II, red squares), together with higher percentages of apoptotic cells (panels III and IV, green squares), implying that the in vivo apoptogenic effect of SU11274 is due to specific inhibition of p-cMET. These findings were corroborated by low immunohistochemical staining with p-cMET of tumor sections from the SU11274-vs. vehicletreated mice ( Figure 6F ).
Discussion
Here, preclinical and clinical evidence showing that the cMET/p-cMET pathway participates to the MM patients' multidrug resistance is provided. Indeed, both cMET and p-cMET are overexpressed in multiresistant R5 and dexamethasone-resistant MM.1R cells compared to their sensitive counterparts ( Figures 1A-E, Supplementary Figure S1 ). We obtained similar results in plasma cells melphalan, and doxorubicin (27) , and show a constitutive activation of cMET receptor ( Figure 1D -E) in terms of the p-cMET content that may entail a therapeutic target (13) (14) . However, R5 cells did not show higher HGF secretion ( Figure 1C ) and differently from RPMI8266 did not reduce pcMET expression upon treatment with a HGF neutralizing antibody: this implies that alternative mechanisms (i.e. receptor activation due to transcriptional upregulation or impaired ligand-receptor internalization (23)) could be involved in constitutive cMET pathway activation in R5 cells.
Notably, cMET gene mutations or amplifications have not been reported in MM PCs so far (13).
The novel selective p-cMET tyrosine-kinase inhibitor SU11274 was able to exert a marked apoptogenic and antiproliferative effect on R5 cells, and to revert their bortezomib, and doxorubicin resistance through a synergistic interaction with these drugs ( Figure 3C Gene expression profiles in SU11274-treated RPMI8226 and R5 cells revealed that these cell lines react differently to the cMET inhibition. A greater number of differentially expressed genes, hence more pathway maps, were enriched in R5 than RPMI8226 cells (Table I ), suggesting that the former are more addicted to the cMET pathway. Phospho-proteome studies also revealed that R5 differ from RPMI8226 cells in 22 out 46 phospho-proteins, which are involved in the jun-activated kinase (JAK), the mitogen-activated protein kinase (MAPK), the phosphatidyl 3-kinase (PI3K)/Akt pathway together with other phospho-proteins of the Src ( Figure 4A ). SU11274 inhibitor modulated differently these signal pathways in R5 vs. RPMI8226 cells ( Figure 4B) , and was able to significantly inhibit phosphorylation of proteins entailed with the MAPK pathway ( Figure 4B ).
These results suggest that multidrug resistant R5 but not RPMI8226 cells become dependent on the cMET receptor for the downstream activation of the MAPK kinase pathway, which is especially involved in MM cell growth and proliferation (38) . Accordingly, SU11274 exerts a potent and persistent antiproliferative activity on R5 but not RPMI8226 cells ( Figure 3B ). 
